Methylthioninium chloride - TauRx
Alternative Names: Methylene blue - TauRx; MTC; Rember; TRx-0014; TRx-014Latest Information Update: 02 Oct 2021
At a glance
- Originator TauRx Therapeutics
- Developer TauRx Therapeutics; University of Aberdeen
- Class Antidementias; Antiparkinsonians; Phenothiazines; Small molecules
- Mechanism of Action Synuclein inhibitors; Tau protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Dementia; Parkinson's disease
Most Recent Events
- 12 Nov 2012 Discontinued - Phase-II for Alzheimer's disease in Singapore (PO)
- 12 Nov 2012 Discontinued - Phase-II for Alzheimer's disease in United Kingdom (PO)
- 12 Nov 2012 Discontinued - Preclinical for Parkinson's disease in Singapore (PO)